U.S. markets open in 49 minutes
  • S&P Futures

    3,785.25
    -42.00 (-1.10%)
     
  • Dow Futures

    30,740.00
    -321.00 (-1.03%)
     
  • Nasdaq Futures

    11,465.50
    -145.75 (-1.26%)
     
  • Russell 2000 Futures

    1,706.70
    -21.80 (-1.26%)
     
  • Crude Oil

    108.76
    +0.33 (+0.30%)
     
  • Gold

    1,803.00
    +1.50 (+0.08%)
     
  • Silver

    19.83
    +0.17 (+0.85%)
     
  • EUR/USD

    1.0289
    -0.0135 (-1.30%)
     
  • 10-Yr Bond

    2.8530
    -0.0360 (-1.25%)
     
  • Vix

    28.78
    +0.07 (+0.24%)
     
  • GBP/USD

    1.1969
    -0.0135 (-1.12%)
     
  • USD/JPY

    135.7540
    +0.0940 (+0.07%)
     
  • BTC-USD

    19,436.64
    -260.80 (-1.32%)
     
  • CMC Crypto 200

    422.18
    +2.04 (+0.48%)
     
  • FTSE 100

    7,094.86
    -137.79 (-1.91%)
     
  • Nikkei 225

    26,423.47
    +269.66 (+1.03%)
     

Evolus to Participate in the H.C. Wainwright Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEWPORT BEACH, Calif., May 11, 2022--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the H.C. Wainwright Global Investment Conference.

Event:

H.C. Wainwright Global Investment Conference

Date:

Tuesday, May 24, 2022

Time:

9:00-9:30 am ET

An audio webcast of this event will be available on the investor relations section of Evolus’ website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company with a customer-centric approach to delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure is a trademark of Daewoong Pharmaceutical Co, Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005100/en/

Contacts

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com